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The chemokine receptors CCR5 and CXCR4 are the major coreceptors for human immunodeficiency virus
(HIV) and simian immunodeficiency virus (SIV). At least 12 other chemokine receptors or close relatives
support infection by particular HIV and SIV strains on CD4 transformed indicator cell lines in vitro.
However, the role of these alternative coreceptors in vivo is presently thought to be insignificant. Infection of
cell lines expressing high levels of recombinant CD4 and coreceptors thus does not provide a true indication
of coreceptor use in vivo. We therefore tested primary untransformed cell cultures that lack CCR5 and CXCR4,
including astrocytes and brain microvascular endothelial cells (BMVECs), for naturally expressed alternative
coreceptors functional for HIV and SIV infection. An adenovirus vector (Ad-CD4) was used to express CD4 in
CD4 astrocytes and thus confer efficient infection if a functional coreceptor is present. Using a large panel
of viruses with well-defined coreceptor usage, we identified a subset of HIV and SIV strains able to infect two
astrocyte cultures derived from adult brain tissue. Astrocyte infection was partially inhibited by several
chemokines, indicating a role for the chemokine receptor family in the observed infection. BMVECs were
weakly positive for CD4 but negative for CCR5 and CXCR4 and were susceptible to infection by the same
subset of isolates that infected astrocytes. BMVEC infection was efficiently inhibited by the chemokine vMIP-I,
implicating one of its receptors as an alternative coreceptor for HIV and SIV infection. Furthermore, we tested
whether the HIV type 1 and type 2 strains identified were able to infect peripheral blood mononuclear cells
(PBMCs) via an alternative coreceptor. Several strains replicated in 32/32 CCR5 PBMCs with CXCR4
blocked by AMD3100. This AMD3100-resistant replication was also sensitive to vMIP-I inhibition. The nature
and potential role of this alternative coreceptor(s) in HIV infection in vivo is discussed.
Human immunodeficiency virus (HIV) and simian immuno-
deficiency virus (SIV) infect cells by inducing fusion of viral
and cellular membranes and releasing the viral core into the
cytoplasm. Fusion is initiated upon interaction of the trimeric
viral envelope glycoprotein and the primary host cell receptor
CD4 (21, 42). A conformational change in gp120 structure
reveals a coreceptor-binding site, and the subsequent interac-
tion with a coreceptor instigates further structural changes in
gp41 and membrane fusion.
The seven-transmembrane G-protein-coupled chemokine
receptors CCR5 and CXCR4 are the major coreceptors used
for HIV and SIV infection in vivo (2, 24, 30). Cell tropism of
HIV and SIV strains is largely determined by the expression of
CD4 and these coreceptors. Cell tropism plays a role in both
virus transmission and disease progression (39). The majority
of transmitted viruses are R5- or M-tropic, highlighted by the
substantial protection from infection observed in individuals
homozygous for a 32-bp deletion in CCR5 (23, 47, 58).
CXCR4-using variants emerge late in disease in up to 50% of
AIDS patients (72). This change in coreceptor use correlates
with disease progression in infected individuals (19, 60), al-
though it is not a prerequisite, as not all infected individuals
demonstrate a coreceptor switch (26). Although primary X4
strains can infect macrophages via CXCR4 (67, 75, 77), these
variants primarily target new populations of T cells that ex-
press CXCR4 but not CCR5, e.g., naive T-cells (7, 52).
Although CCR5 and CXCR4 are the major coreceptors
used in vivo, there are at least 12 other members of the che-
mokine receptor family, and related “orphan” receptors, that
can support infection of indicator cell lines in vitro (5, 16, 27,
55). These include CCR3 (14, 28), CCR8 (55), GPR1 (34, 63),
GPR15 (34), CXCR6 (3, 25), Apj (13, 31), and RDC1 (64). In
general, HIV type 2 (HIV-2) and SIV strains use a wider range
of these alternative coreceptors than HIV-1, frequently as ef-
ficiently as they use CCR5 and/or CXCR4 (16, 53). For HIV-1,
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there is little current evidence to indicate that alternative co-
receptors (other than CCR5 and CXCR4) contribute to viral
replication in vivo (79). The ability of HIV-1 strains to exploit
alternative coreceptors on the surfaces of cell lines therefore
does not provide a true indication of coreceptor usage prop-
erties in vivo. The capacity of naturally expressed coreceptors
(other than CCR5 and CXCR4) to support HIV infection of
primary cell cultures may provide a stronger indication for
their use in vivo. Thus, it has been reported that a maternal
isolate used CXCR6 in addition to CCR5 and CXCR4 on
indicator cell lines and replicated in CCR5 peripheral blood
mononuclear cells (PBMCs) in the presence of a CXCR4 in-
hibitor (61, 79). Similarly, Lee et al. reported that CCR8 sup-
ported infection of primary thymocytes by particular HIV-1
isolates (45).
In this study, we have investigated whether functional core-
ceptors can be detected on different primary or untransformed
human cell cultures. We report the identification of a subset of
HIV and SIV strains that are able to exploit an unknown
coreceptor naturally expressed on brain microvascular endo-
thelial cells (BMVECs) and astrocyte cultures. Moreover sev-
eral of these HIV-1 and HIV-2 strains were able to replicate in
CCR5 PBMCs with CXCR4 blocked by the bicyclam
AMD3100. Replication of such strains was inhibited by the
chemokine vMIP-I, implicating an unknown vMIP-I receptor
as the coreceptor involved.
MATERIALS AND METHODS
Viruses. SF162 is a non-syncytium-inducing molecular clone of HIV-1 which
uses primarily CCR5 as a coreceptor (12). The HIV-1 isolate 2044 utilizes
CXCR4 as a coreceptor and has been previously described (68). GUN-1v is a
variant of the T-cell-line-adapted HIV-1 isolate GUN-1WT, which was isolated by
its ability to infect brain-derived BT cells derived from human meningioma tissue
(71). The HIV-1 strain 89.6 is an R5X4 molecular clone of HIV-1 (18), as is the
isolate HAN-2 (59). The R5X4 HIV-1 isolate P1019 is a pediatric strain isolated
from a 3-year-old child (36). All isolates of HIV-1 used in this study are clade B.
The HIV-2 isolates used here are all Portuguese primary isolates from individ-
uals of West African descent (50, 54). ALI was derived from a patient with
AIDS-related complex. TER, JAU, MIL, and SAB were isolated from AIDS
patients, and the R5X4 isolates JAU, MLC, and ETP originated from symptom-
atic patients (54). The SIV strain SIVmac17Efr is a molecular clone of the isolate
SIVmac239, containing the env and nef genes and the entire 3 long terminal
repeat from the neurovirulent SIVmac239 clone SIV/17E-Br (35). SIVman4 is a
T-cell-line-adapted variant of SIVsmB670 (51). The coreceptor use of most of
the virus isolates used in this study has been previously described (46, 54) and is
summarized in Table 1. All virus stocks were propagated in PBMCs purified from
whole blood by density gradient centrifugation and stimulated for 2 days in
phytohemagglutinin (1 g/ml) (Sigma) and for 2 days in human recombinant
IL-2 (20 U/ml) (Roche, Inc.), with the exception of GUN-1v, which was passaged
in the T-cell line MOLT4 clone 8. The replication-defective adenovirus vector
carrying the human CD4 gene (Ad-CD4) (76) was propagated in the cell line 293.
When cytopathicity was observed, cells were pelleted by centrifugation, the
supernatant was discarded, and the cells were resuspended in fresh Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco Invitrogen Corporation) with 10%
fetal bovine serum (FBS). Cells were lysed by freeze-thawing three times to
release intracellular virus, and cell debris was removed by centrifugation. Ad-
CD4 was titrated on NP2/CCR5 cells (see below) and subsequently challenged
with serially diluted SF162. The Ad-CD4 dilution that conferred maximum
SF162 infection was used in all further experiments.
Cell lines. The human glioma-derived cell lines U87/CD4, stably expressing
the chemokine receptor CCR2b (6, 25), and NP2/CD4, stably expressing CCR3,
CCR5, CCR8, and GPR1 (69), were cultured in DMEM supplemented with 10%
FBS, gentamicin (10 g/ml) (Gibco Invitrogen Corporation), and puromycin (1
g/ml). NP2/CD4/Apj cells were made by transfecting parental NP2/CD4 cells
with a pBabe (puro)-Apj construct and selecting for stable transfectants in
puromycin-containing selection medium. The T-cell line MOLT4 clone 8 was
obtained from the National Institutes of Health (NIH) AIDS Research and
Reference Reagent Program (22, 41) and were maintained in RPMI 1640 me-
dium (Gibco Invitrogen Corporation) containing gentamicin (10 g/ml) (Gibco
Invitrogen Corporation) and 10% FBS.
Primary cells. PBMCs from an individual homozygous for wild-type (wt)
CCR5 or for the 32-bp deletion were prepared from whole blood, drawn under
procedures approved by the University of Massachusetts Medical School Insti-
tutional Review Board, and stimulated with phytohemagglutinin and interleu-
kin-2 as described above. Primary BMVECs (Clonetics Inc.) were maintained in
endothelial cell basal medium 2 supplemented with EGM-2 additives (Clonetics
Inc.). Fetal astrocytes were prepared from primary human fetal brain tissue,
while human adult astrocytes were from temporal lobectomy samples. The use of
fetal brain samples was approved by the University of Massachusetts Institutional
Review Board (no. 10335). Following dissection and removal of blood vessels,
TABLE 1. Coreceptor use by HIV and SIV isolatesa
VIRUS
Titer (FFU/ml) with coreceptor:
CCR5 CXCR4 CCR3 CCR8 GPR1 Apj
HIV-1
SF162 7.2  105 0 8.8  103 2.1  102 0 0
2044 0 1.0  105 0 1.0  102 0 0
89.6 3.0  103 5.0  103 8.0  03 2.6  105 0 1.3  104
GUN-1v 2.2  105 5.5  105 8.0  103 2.5  104 3.0  105 0
HAN-2 1.0  104 2.4  104 1.5  103 3.6  104 2.0  102 0
P1019 2.2  104 2.0  103 1.7  103 1.7  103 4.8  102 0
HIV-2
TER 2.3  105 0 1.6  103 4.6  104 6.7  102 0
ETP 1.7  105 2.5  104 0 4.6  104 0 2.3  103
JAU 4.5  103 4.7  102 1.3  103 2.7  103 1.7  103 2.5  102
ALI 8.0  104 1.0  102 0 0 0 NTb
SAB 0 1.0  105 8.0  103 0 0 NT
SIV (Man4) 2.1  104 1.4  103 1.3  103 0 3.0  102 1.5  102
a Coreceptor use by HIV and SIV isolates that use an alternative coreceptor on BMVEC and astrocyte cultures was determined by titration on the cell line NP2 (for
all of the HIV-1 isolates, HIV-2 TER, ETP, and JAU, and SIVman4), U87 (for HIV-2 ALI and HIV-2 SAB with all coreceptors except CCR3), or GHOST (for HIV-2
SAB with CCR3), stably expressing CD4 and a range of coreceptors. Cells were incubated with 100 l of 10-fold dilutions of virus stock for 3 h before being washed
and incubated at 37°C for 72 h. Infected cells were detected by immunostaining for intracellular p24. The data as presented represent results compiled from several
experiments.
b NT, not tested.
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tissue was resuspended in DMEM and passed through a cell strainer until all cell
clumps were removed. The cell suspension was centrifuged for 5 min at 210  g
before the pellet was resuspended in DMEM–10% FBS and seeded into T25
tissue culture flasks. After cells had adhered, astrocytes were purified from mixed
brain cultures by agitation on a plate shaker at 37°C for 1 to 2 h. Cells were
washed in serum-free medium before incubation for 1 to 2 days in DMEM–10%
FBS and reshaking as described above. Following a further 2-day incubation, the
purity of astrocytes was determined by staining for the astrocytic marker glial
fibrillary acidic protein as described below. Astrocyte cultures were maintained
in DMEM with gentamicin and 10% FBS. Fetal astrocytes showed high plating
efficiencies, whereas recovery from dispersed temporal lobectomy samples was
markedly reduced.
Inhibitors and antibodies. The chemokine RANTES was purchased from
PeproTech Inc., Rocky Hill, N.J. The N-terminally modified RANTES analogue
AOP-RANTES was provided by Amanda Proudfoot, Serono Inc, Geneva, Swit-
zerland. The chemokines I309 and eotaxin and the human herpesvirus 8
(HHV8)-encoded chemokines vMIP-I and vMIP-II were purchased from R&D
Systems, Inc. The CXCR4 antagonist AMD3100 was provided by AnorMED
Inc., Langley, Canada. The small-molecule inhibitor TAK-779 was obtained
through the AIDS Research and Reference Reagent Program, National Institute
of Allergy and Infectious Diseases, NIH (4). The glial fibrillary acidic protein
(GFAP) monoclonal antibody (MAb) used was a rabbit anti-cow GFAP from
Dako. The CCR5 MAb 2D7 was from the NIH AIDS Research and Reference
Reagent Program. The CXCR4 MAb 12G5 was provided through the NIH AIDS
Research and Reference Reagent Program from James Hoxie (32). The CD4
MAb 5A8, directed to the D2 domain of CD4, has been described previously (9).
Q4120 is directed to the N-terminal domain of CD4 and was provided through
the Centralised Facility for AIDS Research from Quentin Sattentau (38).
Immunostaining for fluorescence microscopy. Glass coverslips (13-mm diam-
eter) were placed in the wells of a 24-well plate, sterilized by washing in 70%
ethanol, and rinsed in sterile phosphate-buffered saline (PBS). Cells were plated
at the appropriate density (primary astrocytes at 1  105/ml and cell lines at 4 
104/ml) and left overnight at 37°C to adhere. Cells for GFAP staining were
washed once in PBS before fixation in a cold (40°C) 1:1 methanol-acetone mix
for 5 to 10 min. Immunostaining for cell surface proteins was carried out at 4°C
before fixation in a cold (40°C) 1:1 methanol-acetone mix. Cells were gently
rinsed in PBS before incubation with the appropriate antibody diluted to 5 g/ml
in PBS–1% FBS. Antigen was detected with a goat anti-mouse fluorescein iso-
thiocyanate conjugate (Dako) diluted 1:40 or a swine F(ab)2 anti-rabbit fluo-
rescein isothiocyanate conjugate (Dako) diluted 1:15 in PBS–1% FBS. Images
were captured on a confocal microscope and analyzed with the Confocal Assis-
tant software.
Infectivity assays. Cells were plated the day before use in a 48-well tray at 3 
104 cells/ml in 500 l of the appropriate medium. On the day of infection,
medium was removed from the wells, and cells were infected with 100 l of
10-fold serially diluted cell-free virus. After incubation for 3 h, cells were gently
washed twice with growth medium and incubated for 72 h in 500 l of fresh
medium. For adenovirus expression of CD4, cells were plated at 3  104 cells/ml
in 500 l of the appropriate medium. The following day, medium was removed
and cells were exposed to 100 l of Ad-CD4 for 3 h. The amount of Ad-CD4
added corresponded to the dose of virus that conferred maximum SF162 infec-
tivity to NP2/CCR5 cells. Cells were then rinsed and left overnight at 37°C. The
next day, medium was removed and cells were exposed to HIV as described
above. Infected cells were detected by immunostaining for intracellular p24 as
described below.
Inhibition assays. Adherent astrocytes and BMVECs were seeded the day
before infection in 48-well plates at 3  104 cells/ml in 500 l of the appropriate
medium. On the day of infection, medium was removed and cells were incubated
for 1 h with 75 l of inhibitor (i.e., chemokines, AMD3100, or antibodies) at a
2 final concentration before being exposed to approximately 100 focus-forming
units (FFU) of virus in 75 l for 3 h. Cells were washed once in medium before
the inhibitor was replaced at a 1 concentration (chemokines and small mole-
cules at 500 nM and MAbs at 10 g/ml) and cells were left at 37°C for 72 h.
PBMCs were seeded in 100 l in V-bottom 96-well plates at 106 cells/ml before
centrifugation for 5 min at 210  g and resuspension in 50 l of medium alone
or 2 inhibitor. Following incubation for 1 h at 37°C, 50 l of virus at titers of
104 FFU/ml or higher was added and mixed, and cells were incubated at 37°C for
3 h. After incubation, cells were washed three times by centrifugation for 5 min
at 210  g in medium and resuspended in 150 l of 1 inhibitor. Cells were left
at 37°C, and cell-free supernatant was harvested on days 0, 3, 6, 9, 12, 15, and 18
of infection to monitor virus production. The inhibitor was replenished at each
harvest. Inhibition assays that tested the effect of mouse MAbs, e.g., the anti-
CCR5 2D7, and anti-CD4 Q4120, were directly compared with those for isotype
antibody controls (immunoglobulin G1 [IgG1]). These antibodies were used at 5
g/ml in these inhibition assays. This high concentration of isotype control
nonspecifically reduced the infectivity of tested viruses by up to 50%.
Measurement of virus infectivity. HIV infection of PBMCs was determined by
measuring reverse transcriptase (RT) activity in cell supernatants by an RT
enzyme-linked immunosorbent assay (CavidiTech, Uppsala, Sweden). Infected
adherent cells were detected by immunostaining for intracellular p24 as previ-
ously described (17, 49). In brief, cells were rinsed in PBS before being fixed in
a cold (40°C) 1:1 methanol-acetone mix for 5 to 10 min and rinsed once in PBS
and once in PBS–1% FBS. For HIV-1, cells were stained with a 1:1 mix of
anti-HIV-1 Gag MAbs 38:96K and EF7 (Medical Research Council [MRC]
AIDS Reagent Program, Potters Bar, England) diluted 1:40, while HIV-2-in-
fected cells were stained with a mix of six HIV-2-positive serum samples (WHO
panel C; MRC AIDS Reagent Program) diluted 1:4,000. Infected cells were
detected with a 1:400 dilution of a goat anti-mouse or goat anti-human -galac-
tosidase conjugate for HIV-1 and HIV-2, respectively (Southern Biotechnology
Associates, Inc.) and revealed with an X-Gal (5-bromo-4-chloro-3-indolyl--D-
galactopyranoside) substrate (PBS with 3 mM potassium ferricyanide, 3 mM
potassium ferrocyanide, 1 mM magnesium chloride, and 0.5 mg of X-Gal per
ml).
RT-PCR. Total cellular RNA was extracted from 1  106 to 5  106 cells by
using the RNeasy kit from Qiagen, and mRNA was isolated by using the Oligotex
kit from Qiagen. Specific mRNA sequences were amplified with the primers
described in Table 2, using the Titanium one-step RT-PCR kit (Clontech). The
housekeeping glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was
amplified from all cell samples as a positive control, and negative controls were
primers for a gene known not be expressed in that cell type. All reactions were
carried out in duplicate, with control reactions taking place on untranscribed
mRNA to demonstrate the absence of contaminating genomic DNA. All reac-
tion products were run on a 1.4% agarose gel with a 100-bp DNA ladder (New
England Biolabs).
RESULTS
Lack of CCR5 and CD4 on cultured astrocytes by immuno-
staining. Untransformed cultured fetal astrocytes (F01) and
cells derived from adult temporal lobectomies (samples 001A
and 004.2) were tested for their expression of the astrocyte
marker GFAP. Figure 1 shows that fetal astrocytes were
strongly positive, while both adult cultures showed weaker and
more diffuse staining, consistent with the observations of Mar-
riott et al. (48). We also tested for CCR5, CXCR4, and CD4
expression on each of the untransformed astrocyte cultures
and found that purified fetal astrocytes (F01) cultured for 2
weeks expressed neither CCR5 nor CD4 but were weakly pos-
itive for CXCR4, as shown previously (Fig. 1) (53). CD4,
CCR5, and CXCR4 were not detected on either of the adult
brain-derived cultures 001A and 004.2.
CD4 expression on cultured astrocytes confers sensitivity to
a subset of HIV and SIV strains. Astrocytes do not usually
express CD4 and therefore support only an inefficient infection
by particular HIV-1 strains (56, 74). The chemokine receptor
expression profile of astrocytes is controversial, and the role of
coreceptors in the observed low-level infection is unclear (8,
56). In order to determine if the cultured fetal and adult
GFAP-positive cultures express functional coreceptors, we
used an Ad-CD4 vector to express CD4 on these cells. As seen
in Fig. 2A, infection of the cell line NP2/CCR5 with Ad-CD4
is sufficient to confer infection by R5 viruses to levels compa-
rable to those seen with NP2 cells stably expressing both CD4
and CCR5. By the same principle, infection of astrocyte cul-
tures with Ad-CD4 enables the screening of a range of HIV
and SIV isolates for their capacity to use functional corecep-
tors expressed on astrocytes that lack CCR5 (fetal) or both
CCR5 and CXCR4 (adult). Adult astrocyte cultures (001A and
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004.2) preinfected with Ad-CD4 were resistant to HIV-1
strains that predominantly used CCR5 (SF162) or CXCR4
(2044). In contrast, three R5X4 HIV-1 strains (P1019, HAN-2,
and GUN-1v) and several HIV-2 and SIV strains (TER, ETP,
SIVman4, and SIVmac17Efr) were able to infect adult astro-
cytes 001A and, to various extents, 004.2 (Fig. 2B and C). The
fetal astrocyte culture F01 weakly expressed CXCR4 (Fig. 1),
and adenovirus-mediated expression of CD4 conferred sensi-
tivity to all isolates that use CXCR4, including the HIV-1 X4
isolate 2044 (Fig. 2D). However, it is likely that the HIV-2
strain TER and SIVman4 exploit an alternative coreceptor for
infection of fetal astrocytes, since TER does not use CXCR4
on standard CD4 indicator cell lines (54), and CXCR4 use by
SIVman4 is inefficient and at least 1,000 times less than CCR5
use (data not shown).
Infection of fetal and adult astrocytes by HIV-1, HIV-2, and
SIV strains in the absence of CD4 expression. Low-level CD4-
independent infection of brain cultures has been reported for
various HIV and SIV strains (15, 56). Therefore, we also tested
whether fetal and adult astrocytes supported infection by the
same panel of HIV and SIV isolates in the absence of adeno-
virus-mediated CD4 expression. These cultures were negative
for CD4 expression by immunohistochemical methods, and
infection by most strains was weak, as expected (Fig. 3). The
HIV-1 strains SF162 (R5) and 2044 (X4) did not infect either
the adult or fetal astrocytes. The R5X4 isolates HAN-2 and
P1019, as well as the HIV-2 strain TER and the SIV isolates
Man4 and 17Efr, gave variable but low infectivity titers on all
three astrocyte cultures. The HIV-1 isolate GUN-1v was able
to infect both adult astrocyte cultures 004.2 and 001A, even
though infection of coreceptor indicator cell lines in the ab-
sence of CD4 was negative (data not shown).
Infection of fetal and adult astrocytes is reduced by chemo-
kine receptor ligands. In order to identify the possible core-
ceptor(s) being exploited for infection, we tested a range of
chemokine receptor ligands for their capacity to block infec-
tion by HIV-1 GUN-1v. A common feature of the HIV and
SIV strains that infected astrocytes was their capacity to exploit
CCR3, CCR8, and GPR1 as coreceptors on indicator cell lines
(in addition to CCR5 and sometimes CXCR4). We therefore
included ligands that bind these chemokine receptors in the
inhibition assays. The activities of all coreceptor-specific che-
mokines and antibodies were determined by carrying out con-
trol inhibitions on appropriate coreceptor-expressing cell lines.
CCR3- and CCR8-mediated HIV infection was selectively in-
hibited by the ligands eotaxin and I309, respectively (data not
shown). In comparison, vMIP-I (an HHV8-encoded chemo-
kine) inhibited infection of control cell lines expressing CCR8,
GPR1, and CXCR6, as previously reported (66), and weakly
blocked CCR3-mediated infection (data not shown).
GUN-1v infection of adult astrocytes 001A pretreated with
Ad-CD4 was reduced to approximately 50% of the levels seen
in the absence of inhibitors by both vMIP-I (which binds
CCR8, GPR1, and CXCR6) and RANTES (which binds
CCR5, CCR1, CCR3, and CCR9). The ligand eotaxin (CCR3,
D6) also reduced infectivity to approximately 60%. (Fig. 4A).
TAK-779, the CCR5 small-molecule inhibitor, had no effect on
001A infection despite inhibiting GUN-1v infection of CCR5-
expressing indicator cell lines by 100% (data not shown). In
addition, the CCR5-specific MAb 2D7 failed to block astrocyte
TABLE 2. Oligonucleotide sequences used for the amplification of HIV and SIV receptors and coreceptors
Primer Sequence (533) Product size (bp)
GAPDH TGGATATTGCCATCAATGACC 457
GATGGCATGGACTGTGGTCATG
CD4 TCAGGGAAAGAAAGTGGTGC 170
AAGAAGGAGCCCTGATTTCC
CCR5 CTTCATTACACCTGCAGCTCT 182 (wild type), 150 (32)
CACAGCCCTGTGCCTCTTCTT
CXCR4 TAGATATCTTACCATGGAGGGGATCAG 1,044
TAGCGGCGCTTAGCTGGAGTGAAAACTTG
CCR8 GCAAGTTGCTCCTTGCTGTC 710
CATGGGTGGCATAAGTCAGC
CCR3 GCTGATACCAGAGCACTGATG 834
CAACAAAGGCGTAGATCACCG
GPR1 CCAGCTGGGAGTTGTTGTTCACT 1,068
GCTGTTTCCAGGAGACACAG
GPR15 ATGGACCCAGAAGAAACTTC 1,100
TTAGAGTGACACAGACCTC
CXCR6 CAGGCATCCATGAATGGGTGT 766
CAAGGCTATAACTGGAACATGCTG
RDC1 AAGAAGATGGTACGCCGTGTCGTCTGCATCCTG 280
CTGCTGTGCTTCTCCTGGTCACTGGACGCCGAG
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FIG. 2. CD4 expression on astrocytes confers susceptibility to infection with HIV and SIV. (A) The activity of Ad-CD4 was tested by pretreating
NP2/CCR5 cells with Ad-CD4 for 3 h, rinsing, and incubating overnight. Ad-CD4-pretreated and untreated NP2/CCR5 cells, as well as NP2 cells
stably expressing CD4 and CCR5, were exposed to the R5-using HIV-1 strain SF162 for 3 h, and infected cells detected by p24 immunostaining
were counted after 72 h. (B) Untransformed GFAP-positive adult astrocytes 001A and 004.2 were pretreated with Ad-CD4 before infection with
the HIV-1, HIV-2, and SIV strains shown. After 72 h, cells were fixed and stained for intracellular viral antigens. (C and D) The titer of each HIV
or SIV isolate was assessed on adult astrocytes 001A and 004.2 (C) and fetal astrocytes F01 (D). Cells were exposed to Ad-CD4 and infected as
described above. All HIV and SIV isolates tested had titers of between 1  105 and 5  105 FFU/ml on NP2/CD4 coreceptor-expressing indicator
cells (Table 1). Infected cells were detected by immunostaining for viral antigens and counted. All data are representative of those from at least
three independent experiments.
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infection in comparison to an IgG1 isotype control. Taken
together, these data confirm that the inhibition observed by
RANTES is not due to the expression and use of CCR5 on
these cells. Astrocyte infection was not affected by the CXCR4
antagonist AMD3100 or the CCR8-specific ligand I309. The
same chemokines that weakly reduced infection of CD4 adult
astrocytes 001A (vMIP-I, eotaxin, and RANTES) also inhib-
ited infection in the absence of CD4 by between 50 and 60%
(Fig. 4B). Intriguingly, infection of CD4 001A cells was com-
pletely blocked by the CD4 MAb Q4120, indicating the pres-
ence of low levels of CD4 undetectable by immunostaining
(Fig. 1) but sufficient to explain the observed infection by the
HIV-1 strains GUN-1v and HAN-2 in the absence of adeno-
virus-mediated CD4 expression. As seen in Fig. 4A, CD4
astrocyte infection was also unaffected by 2D7. Infection of the
fetal astrocyte preparation F01 by GUN-1v was reduced to less
than 10% of control levels by AMD3100 and was minimally
affected by RANTES, I309, and vMIP-I, confirming that
CXCR4 conferred the majority of infection in these cells (Fig.
4C). The observation that adult astrocyte infection can be
inhibited by chemokines implies a role for a chemokine recep-
tor(s) in virus entry into these cells. However, weak inhibition
was observed with several chemokines, all of which interact
with a range of chemokine receptors (vMIP-I, RANTES, and
eotaxin), suggesting that the chemokine receptor exploited for
infection of astrocytes is not a major target for these chemo-
kines.
BMVECs support infection by the same viruses shown to
infect astrocytes via an unidentified coreceptor. We next tested
the ability of primary BMVECs to support infection by a range
of HIV-1, HIV-2, and SIV isolates. No infection by HIV-1 and
HIV-2 isolates that predominantly use CCR5 or CXCR4 was
observed. However, the same subset of viruses that infected
adult astrocytes also replicated in BMVECs. These included
R5X4 HIV-1 strains (GUN-1v and HAN-2), HIV-2 strains
(TER), and SIV strains (17Efr) (Fig. 5A). In addition, the
R5X4 HIV-2 isolates JAU and MLC and the SIV variant
SIVmac316 infected BMVECs. BMVEC infection by GUN-1v
was completely inhibited by vMIP-I (Fig. 5B) but was unaf-
fected by ligands for CCR5 (AOP-RANTES), CXCR4
(AMD3100), and CCR8 (I309), despite their ability to block
infection of coreceptor-expressing cell lines (data not shown).
The CCR3 ligand eotaxin reduced BMVEC infection by ap-
proximately 30%; however, the chemokine analogue vMIP-II,
a more potent inhibitor of CCR3, had no effect on infection
(43, 66). BMVEC infection was reduced to less than 5% by the
CD4 MAbs Q4120 (D1) and 5A8 (D2/3), indicating that CD4
was present on the cell surface at levels high enough to support
FIG. 3. Infection of fetal and adult astrocytes by HIV-1, HIV-2, and SIV without Ad-CD4 pretreatment. Adult 004.2 and 001A astrocytes
(A) and fetal F01 astrocytes (B) were seeded the day before infection with a panel of HIV and SIV isolates for 3 h. Infected cells were detected
by immunostaining for intracellular viral p24 after 72 h. Titers are representative of those from three independent experiments. All viruses tested
had infectivity titers of between 1  105 and 5  105 FFU/ml on NP2/CD4 coreceptor-expressing indicator cells.
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FIG. 4. Infection of CD4 astrocytes is partially inhibited by vMIP-I and RANTES. Adult-derived astrocytes 001A either pretreated with
Ad-CD4 (A) or untreated (B) and fetal astrocytes F01 (C) were preincubated with a range of chemokines or small-molecule inhibitors at 500 nM
or with antibodies at 5 g/ml before being exposed to the HIV-1 isolate GUN-1v. Infected cells were detected by immunostaining for p24 at 72 h
postinfection. One hundred percent infection represents the titer in the absence of inhibitor and was approximately 150 FFU. All values were
calculated with respect to this control. All samples were done in duplicate, and the error bars represent the standard errors of the means.
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the efficient infection observed by the HIV and SIV strains
shown in Fig. 5. The corresponding antibody isotype control,
IgG1, had no effect on BMVEC infection. Infection of BM-
VECs therefore identifies the same subset of HIV-1, HIV-2,
and SIV strains that infect GFAP astrocytes. Complete inhi-
bition of BMVEC infection by vMIP-I, as well as the lack of
inhibition by potent ligands for CCR5 and CXCR4, confirms
that an alternative coreceptor is responsible for virus entry.
A subset of HIV and SIV isolates can infect 32/32 CCR5
PBMCs with CXCR4 blocked by AMD3100. The experiments
described above provide evidence that BMVECs and astro-
cytes naturally express alternative coreceptors that are func-
tional for a subset of HIV-1 strains. Since these cells are not
the major targets for HIV-1 in vivo, we tested whether the HIV
and SIV isolates had the capacity to exploit an alternative
coreceptor(s) on PBMCs. For this we used PBMCs prepared
from an individual homozygous for the 32-bp deletion in CCR5
(32/32 CCR5) and blocked CXCR4 by treatment with
AMD3100. The R5 HIV-1 isolate SF162 was unable to infect
these cells, since they do not express CCR5 (data not shown).
Infection of wt/wt CCR5 PBMCs by SF162 was not inhibited by
the ligand AMD3100 (CXCR4) or vMIP-I (CCR8, GPR1, and
CXCR6), either alone or in combination (Fig. 6A). Together
these data demonstrate that SF162 infection of PBMCs is
entirely CCR5 dependent. On 32/32 CCR5 PBMCs, the X4
strain 2044 was efficiently inhibited by AMD3100 but not
vMIP-I, although a slight delay in the rate of replication of this
virus was noted (Fig. 6B). The HIV-1 isolate HAN-2 and
FIG. 5. BMVECs support infection by the same subset of HIV and SIV isolates that infect astrocytes. (A) Untransformed BMVECs were
exposed to HIV and SIV strains, and intracellular viral antigens were detected by immunostaining following a 72-h incubation. (B) The sensitivity
of BMVEC infection to chemokine inhibition was determined by preincubating cells with chemokines or small molecule inhibitors at 200 nM or
with CD4 MAbs at 5 g/ml before incubation with the HIV-1 isolate GUN-1v. Infections were performed in duplicate, and error bars represent
the standard errors of the means. Results are representative of those from at least two independent experiments.
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HIV-2 TER replicated in the presence of AMD3100 (Fig. 6C
and E). A second HIV-1 isolate, P1019, consistently replicated
in the presence of AMD3100, albeit at low levels (Fig. 6D).
Replication by each of these viruses was completely inhibited
when cells were pretreated with vMIP-I in addition to
AMD3100, yet pretreatment with I309 in addition to
AMD3100 had no effect on any of the isolates tested (data not
shown). We also tested GUN-1v; however, this T-cell-line-
adapted virus replicated poorly in both wt/wt and 32/32
CCR5 PBMCs. GUN-1v replication eventually ensued after a
long lag phase; however, the impact of adaptive changes oc-
curring during this lag time on GUN-1v coreceptor use is
unclear. GUN-1v data were therefore omitted from this study.
The results described above thus show that the primary HIV-1
and HIV-2 strains that infect astrocytes and BMVECs are also
able to exploit an alternative coreceptor on PBMCs, a major
target for HIV infection in vivo.
Analysis of HIV and SIV receptor expression on untrans-
formed cell types. RT-PCR was carried out on mRNA ex-
tracted from the three astrocyte cultures, BMVECs, 32/32
PBMCs, and macrophages, to determine the pattern of HIV
coreceptor expression. All mRNA preparations were positive
for the housekeeping GAPDH gene (Fig. 7A). CD4 was found
to be strongly expressed in 32/32 CCR5 PBMCs and mac-
rophages, as expected, but, surprisingly, also in the adult as-
trocytes 004.2 (Fig. 7B). BMVECs and the adult astrocyte
culture 001A were very weakly positive for CD4, explaining the
inhibition observed with anti-CD4 antibodies (Fig. 4B and 5B,
respectively). A truncated CCR5 signal was detected for 32/
32 PBMCs and macrophages but not for any of the other cell
cultures tested. CXCR6 expression was detected in PBMCs
only. CXCR4 mRNA was expressed in 32/32 PBMCs and
macrophages, as well as in the fetal astrocyte culture F01.
Although CCR3 and CCR8 were undetectable on 32/32
PBMCs after 25 cycles, a signal was detected after amplifica-
tion for 35 cycles (Fig. 7C). All other coreceptors screened for,
including CCR3, CCR8, GPR1, and GPR15, were negative on
all other primary cell cultures after 25 and 35 cycles (Fig. 7C).
The orphan receptor RDC1 was detected in 32/32 PBMCs,
in the fetal F01 astrocytes, and weakly in the adult 004.2 as-
trocytes. In contrast to other studies (64), the parental NP2/
CD4 cell line was also positive for this receptor. mRNA de-
tection for each of the coreceptors tested here therefore did
not correlate with HIV or SIV infection via the alternative
coreceptor. We thus conclude that an as-yet-unidentified re-
ceptor for vMIP-I is partially (astrocytes) or wholly (BMVECs
and PBMCs) responsible for infection of several untrans-
formed cell cultures.
FIG. 6. Productive infection of 32/32 CCR5 PBMCs by HIV and SIV strains with CXCR4 blocked. 32/32 CCR5 or wt/wt CCR5 PBMCs
were preincubated for 1 h with medium alone or the inhibitor AMD3100, vMIP-I, or AMD3100 plus vMIP-I at 1,000 nM before addition of virus.
(A) wt/wt CCR5 PBMCs were infected in triplicate with the R5 HIV-1 strain SF162. (B to G) 32/32 CCR5 PBMCs were infected in triplicate
with all other viruses (2044, HAN-2, P1019, TER, ETP, and SIVman4). All virus stocks had titers of between 104 and 105 FFU/ml on
NP2/CD4/CCR5 or NP2/CD4/CXCR4 indicator cell lines. Supernatant was removed every 3 days up to day 18, and virus production was measured
by RT enzyme-linked immunosorbent assay. All points represent the average for triplicate samples, and infections are representative of at least
two independent infections.
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DISCUSSION
A wide range of different seven-transmembrane G-protein-
coupled chemokine receptors function as coreceptors for HIV
infection of indicator cell lines in vitro. Many HIV-2 and SIV
strains are particularly promiscuous for different coreceptors in
such assays; however, HIV-1 strains can also use a variety of
alternative coreceptors (16, 53), e.g., CCR3, CCR8, and
FIG. 7. mRNA expression of HIV and SIV receptors and coreceptors in primary cell types. RT-PCR was used to test for chemokine receptor
mRNA expression. (A) Amplification of GAPDH served as a control for intact mRNA. (B) The presence of chemokine receptor mRNA in
32/32 CCR5 PBMCs and macrophages, astrocytes, and BMVECs was determined, with mRNA from coreceptor-expressing cell lines NP2/CD4
(CCR5, CXCR4, CCR3, CCR8, and GPR1) and GHOST (CXCR6 and GPR15) acting as positive controls. NP2/CD4 cells naturally expressed
RDC1. The primers used are shown in Table 2. Lanes MWM, 100-bp molecular size DNA ladder. Each experiment was carried out with negative
(water) (lanes ) and positive (mRNA from cells expressing the specific receptor) (lanes ) controls, as well as with the parental NP2/CD4 cells
as a cellular negative control. The absence of contaminating genomic DNA was confirmed by carrying out all RT-PCRs on untranscribed mRNA
(data not shown).
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CXCR6. Although some of these coreceptors are expressed on
CD4 primary cells (1, 34, 61), there is little current evidence
to suggest they are used by HIV-1 in vivo. Thus, the ability of
particular HIV-1 strains to exploit alternative coreceptors for
infection of cell lines in vitro does not provide a true indication
of virus coreceptor use in vivo. We therefore analyzed several
untransformed cell cultures for natural expression of func-
tional alternative coreceptors that support HIV and SIV infec-
tion.
Astrocytes established from adult temporal lobectomy sam-
ples and untransformed BMVEC cultures do not express ei-
ther CCR5 or CXCR4 and thus represent suitable target cells
to test for the presence of alternative coreceptors. BMVECs
and adult astrocytes expressing CD4 (via Ad-CD4) were resis-
tant to infection by HIV and SIV strains that predominantly
utilize CCR5 or CXCR4 alone. Both BMVECs and adult as-
trocytes were susceptible to infection by a subset of R5X4
HIV-1 strains, including two primary isolates (HAN-2 and
P1019) as well as GUN-1v. GUN-1v is a variant virus isolated
in vitro by its capacity to infect a wider range of host cells,
including BT cells (human CD4 meningioma-derived cells)
(65, 71). GUN-1v infection of BMVECs was sensitive to inhi-
bition by vMIP-I (an HHV8-encoded chemokine), suggesting
that a receptor for this ligand is important for infection of
these cells. In contrast, astrocyte infection by GUN-1v was
reduced only approximately 50% by vMIP-I. This lack of com-
plete inhibition by vMIP-I suggests either that the vMIP-I
receptor (implicated for infection of BMVECs) is not solely
responsible for astrocyte infection or that vMIP-I only weakly
inhibits this receptor as expressed on astrocytes.
Infection of astrocytes was also reduced approximately 50%
by the chemokines RANTES and eotaxin. These ligands each
bind several chemokine receptors (CCR1, CCR3, CCR5, and
CCR9 for RANTES and CCR3 and D6 for eotaxin), indicating
a role for this subclass of receptor in the infection of astrocytes.
Although CCR5 expression was not detected on these astro-
cytes, several groups have reported expression on astrocytes in
situ in the brain, which is lost rapidly in culture (8, 29, 44). The
lack of inhibition by the CCR5 small-molecule inhibitor TAK-
779, as well as by the CCR5-specific MAb 2D7, confirms that
the weak inhibition by RANTES was not due to the presence
of low levels of CCR5.
There is evidence that astrocytes become persistently in-
fected by HIV-1 in vivo, particularly in pediatric AIDS (57, 70,
74). Since R5 viruses are predominant in the brain (1, 37, 62),
it is possible that these astrocytes are infected in vivo via
CCR5. Nevertheless, the alternative coreceptor demonstrated
on these CCR5 cultured astrocytes may potentially confer
infection of astrocyte subsets critical for brain homeostasis and
thus have an impact on neuropathology. In this study we used
MAbs that detect p24 as a marker for HIV-1 infection. Since
p24 is a late gene product, our results show that the astrocyte
infection observed here in vitro is not restricted to the early
phase of viral replication and expression of early gene prod-
ucts, thus confirming the observations of Canki et al. (10).
Since BMVECs and astrocytes are not major targets for
HIV-1 in vivo, we sought evidence for use of the alternative
coreceptor on primary PBMCs. Other studies have demon-
strated the ability of some SIV strains to infect PBMCs lacking
CCR5 via an alternative coreceptor, in a donor-dependent
manner (11, 78). In some instances CXCR6 was implicated as
the coreceptor involved (79, 80). In confirmation, several
HIV-1 and HIV-2 isolates identified here that exploit an alter-
native coreceptor(s) for BMVEC and astrocyte infection were
able to replicate in PBMCs that lack CCR5, with CXCR4
blocked by AMD3100. The X4 isolate 2044 was consistently
sensitive to inhibition by AMD3100, although low-level resid-
ual replication was sometimes detected even in the presence of
AMD3100. However, AMD3100-resistant replication in PBMCs
by the isolates HAN-2, P1019, TER, and Man4 was not due to
residual use of CXCR4, since such replication was inhibited by
vMIP-I, a chemokine that does not interact with CXCR4 (20,
67). Our observations therefore provide evidence that an al-
ternative coreceptor is active for infection of PBMCs by the
HIV and SIV strains described.
The identity of the alternative coreceptor remains to be
conclusively elucidated. A hallmark of the BMVEC and
PBMC infection via an alternative coreceptor demonstrated
here was the sensitivity to inhibition by vMIP-I. To date,
vMIP-I has been reported to inhibit HIV infection mediated
through CCR8 (20, 33) as well as GPR1 and CXCR6 (66).
GUN-1v and the other HIV and SIV strains, identified here by
their capacity to use alternative coreceptors, were able to use
CCR8 and GPR1 (as well as other coreceptors) in addition to
CCR5 and CXCR4 as coreceptors on cell lines. Furthermore,
GUN-1v has previously been reported to use alternative core-
ceptors for infection of astroglial U87 cells, primary mesengial
kidney cells, and BT cells. CCR8 was implicated as a corecep-
tor for BT infection (40) and GPR1 was implicated as a core-
ceptor for mesengial cell infection (73); however, inhibition by
ligands to these coreceptors was not demonstrated. Our ob-
servations that the CCR8 ligand I309 had no effect on the
replication of any HIV or SIV isolate in BMVECs or 32/32
PBMCs, alone or in combination with AMD3100, despite be-
ing able to inhibit infection of a CCR8-expressing indicator cell
line (data not shown) implies that vMIP-I is able to inhibit HIV
infection of PBMCs via another chemokine receptor.
We also attempted to correlate coreceptor mRNA detection
in PBMCs, BMVECs, and astrocytes with infection by this
subset of HIV and SIV strains. None of the presently known
vMIP-I receptors (CCR8, GPR1, and CXCR6) were detected
by RT-PCR in BMVECs. mRNA for CCR8 was detected in
the 32/32 PBMCs; however, the CCR8-specific chemokine
I309 had no effect on viral replication in either PBMCs or
BMVECs. 32/32 CCR5 PBMCs were also positive for ex-
pression of CXCR6, a coreceptor previously implicated as be-
ing responsible for replication of a maternal HIV-1 isolate (61,
79, 80). However, the CXCR6 ligand CXCL16 failed to block
replication of vMIP-I-sensitive virus strains on 32/32 CCR5
PBMCs even though infection of CXCR6-expressing cell lines
was efficiently inhibited (data not shown). Finally, mRNA for
GPR1 was not detected in either BMVECs or PBMCs. We
therefore believe that an as-yet-unidentified vMIP-I receptor is
responsible for the HIV and SIV infection of these cells. An
alternative, albeit less likely, explanation is that vMIP-I induces
down-modulation of a different receptor or induces intracellu-
lar signaling responses that negatively affect viral replication.
However, previous studies have demonstrated that vMIP-I has
no effect on chemokine-induced intracellular calcium signaling
via the chemokine receptors CCR2, CCR4, CCR5, CCR7,
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CXCR2, CXCR3, and CXCR4 on PBMCs (20). Although
vMIP-I did desensitize CCR8-mediated signaling, its ineffec-
tiveness against such a large range of chemokine receptors
suggests that receptor desensitization is not the mechanism of
inhibition observed here.
All viruses that we found to use an alternative coreceptor(s)
are R5X4, with the exception of HIV-2 TER, an isolate that
readily acquires CXCR4 use in culture. We believe that an
alternative coreceptor(s) may be exploited late in disease in
addition to, or instead of, CXCR4 (like TER). The role of the
expansion in coreceptor use may therefore contribute to the
broadening of cell tropism late in disease, while a role in
neuropathogenesis should also be considered. Moreover, the
alternative coreceptor should be considered as a potential es-
cape route from new therapeutic CCR5 and CXCR4 inhibitors
currently undergoing clinical trials (34).
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